It overcomes multidrug‐resistance (MDR) in tumor cells, elevates paclitaxel concentration within the cells, and enhances antitumor activity when combined with taxol. Additionally, it reduces P‐gp content and targets mechanisms linked to drug resistance. The gene discussed is PGP; the disease is neoplasm.